CTOs on the Move

CB Scientific

www.cbscientificinc.com

 
A publicly traded (OTC: CBSC) company providing innovative products and services in the ambulatory non-invasive cardiac monitoring space. CB Scientific, Inc., through its US and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
James Ott
Chief Technology Officer Profile

Similar Companies

Saringer Life Science Technologies

Saringer Life Science Technologies Inc. is a Oakville, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Revolution Enterprises

Revolution Cannabis is committed to producing the cleanest, most reliable and efficacious medical cannabis products. Our team is comprised of passionate cannabis cultivation, public health, and research professionals united by a desire to cultivate health and happiness through the science of cannabis. Revolution`s core values permeate every facet of operations spanning cultivation, breeding, production, packaging, labeling, community outreach, and more.

Multi-Pack

Multi-Pack is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GAS Latam Group

GAS Latam Group is a Laredo, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EnteroMedics

EnteroMedics® Inc. is the developer of vBloc® neurometabolic therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, a first-in-class weight loss treatment for obesity and obesity related risk factors, such as high blood pressure or high cholesterol levels. vBloc Therapy is a non-anatomy altering or restricting, reversible therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals. vBloc Therapy is now approved by the Food and Drug Administration for weight loss in adults with a BMI of 40 to 45 kg/m2 or a BMI of 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels.* *Individuals should have first tried to lose weight by diet and exercise in a supervised program within the last 5 years before receiving the Maestro System.